FDA panel recommends approval of J&J/Bayer anti-clotting drug – Government health advisers said Thursday the benefits of an experimental anticlotting drug from Johnson & Johnson outweigh its risks, including bleeding and incomplete data about liver side effects. The Food and Drug Administration’s panel of cardiology experts voted 15 to 2 in favor of J&J’s rivaroxaban, which if approved, would be the first new pill-based anticlotting drug in a half-century
Stiefel putting itself up on the block? – Stiefel Laboratories Inc, a privately held pharmaceutical maker, is considering selling itself in a deal that could be worth several billion dollars, the Wall Street Journal said, citing people familiar with the matter. The potential sale has drawn interest from a number of major drug companies, including Johnson & Johnson, Novartis AG, and GlaxoSmithKline PLC.
The new Massachusetts sales and marketing rules are out for pharma. Let the compliance begin.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff
Leave a Reply